Rodeghiero Francesco, Stasi Roberto, Gernsheimer Terry, Michel Marc, Provan Drew, Arnold Donald M, Bussel James B, Cines Douglas B, Chong Beng H, Cooper Nichola, Godeau Bertrand, Lechner Klaus, Mazzucconi Maria Gabriella, McMillan Robert, Sanz Miguel A, Imbach Paul, Blanchette Victor, Kühne Thomas, Ruggeri Marco, George James N
Department of Hematology, San Bortolo Hospital, Vicenza, Italy.
Blood. 2009 Mar 12;113(11):2386-93. doi: 10.1182/blood-2008-07-162503. Epub 2008 Nov 12.
Diagnosis and management of immune thrombocytopenic purpura (ITP) remain largely dependent on clinical expertise and observations more than on evidence derived from clinical trials of high scientific quality. One major obstacle to the implementation of such studies and in producing reliable meta-analyses of existing data is a lack of consensus on standardized critical definitions, outcome criteria, and terminology. Moreover, the demand for comparative clinical trials has dramatically increased since the introduction of new classes of therapeutic agents, such as thrombopoietin receptor agonists, and innovative treatment modalities, such as anti-CD 20 antibodies. To overcome the present heterogeneity, an International Working Group of recognized expert clinicians convened a 2-day structured meeting (the Vicenza Consensus Conference) to define standard terminology and definitions for primary ITP and its different phases and criteria for the grading of severity, and clinically meaningful outcomes and response. These consensus criteria and definitions could be used by investigational clinical trials or cohort studies. Adoption of these recommendations would serve to improve communication among investigators, to enhance comparability among clinical trials, to facilitate meta-analyses and development of therapeutic guidelines, and to provide a standardized framework for regulatory agencies.
免疫性血小板减少性紫癜(ITP)的诊断和管理很大程度上仍依赖于临床专业知识和观察,而非来自高质量科学临床试验的证据。开展此类研究以及对现有数据进行可靠的荟萃分析的一个主要障碍是,在标准化的关键定义、结局标准和术语方面缺乏共识。此外,自新型治疗药物(如血小板生成素受体激动剂)和创新治疗方式(如抗CD20抗体)问世以来,对比较性临床试验的需求急剧增加。为克服当前的异质性,一个由知名临床专家组成的国际工作组召开了一次为期两天的结构化会议(维琴察共识会议),以确定原发性ITP及其不同阶段的标准术语和定义、严重程度分级标准、具有临床意义的结局和反应。这些共识标准和定义可用于临床研究试验或队列研究。采纳这些建议将有助于改善研究者之间的沟通,提高临床试验之间的可比性,促进荟萃分析和治疗指南的制定,并为监管机构提供一个标准化框架。